stronger warning about potential hepatotoxicity in patients taking Duract (bromfenac)

The FDA is requiring a stronger warning about potential hepatotoxicity in patients taking Duract (bromfenac).

Duract is the new NSAID that just came out last fall. It's approved only for SHORT-TERM use...similar to Toradol (ketorolac).

Now there are several reports of severe hepatitis and liver failure in patients taking Duract for longer than a month.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote